TTR

Across TCGA pan-cancer cohorts, TTR RNA is linked to patient survival in 21 of 34 cancer types, making it the most broadly survival-associated TTR data layer compared with 3 for mutation status and 6 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher TTR RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated TTR expression acts as an unfavorable survival marker, although some lineages such as LIHC and PAAD show a favorable association.

LIHC, UVM, and LGG are the cancer types where TTR RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Tertile	All	0.532	0.354	<.001	60	view →
UVM	DFS	Tertile	All	0.385	0.876	.004	42	view →
LGG	OS	Median	All	0.754	0.867	<.001	39	view →
KIRP	OS	Tertile	All	0.891	0.982	.004	33	view →
HNSC	OS	Quartile	II,III,IV	0.640	0.779	.007	33	view →
PAAD	DFS	Tertile	All	0.500	0.224	.002	28	view →
SCLC	OS	Median	II,III,IV	0.630	0.307	.007	24	view →
STAD	OS	Quartile	II,III,IV	0.322	0.665	.005	19	view →
TGCT	DFS	Quartile	All	0.486	0.763	.002	18	view →
DLBC	OS	Median	All	0.630	1.000	.038	14	view →
BRCA	OS	Median	All	0.618	0.550	.021	5	view →
LUSC	OS	Quartile	II,III,IV	0.255	0.430	.026	5	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 21 lineages.

TTR–LIHC (DFS)

Open the LIHC breakdown →